Second mutation in BRAF-mutated melanoma doesn't contribute to resistance

April 1, 2012

A second mutation found in the tumors of patients with BRAF-mutated metastatic melanoma does not contribute to resistance to BRAF inhibitor drugs, a finding that runs counter to what scientists expected to be true.

The study by researchers at UCLA's Jonsson Comprehensive Cancer Center found that patients with the in both the MEK1 and BRAF genes respond as well to the inhibitors as patients with the BRAF mutation alone.

Another surprising finding is that the MEK1 and BRAF mutations exist together in these patients, despite the fact that they drive the same cell signaling pathway. That discovery also bucks , said study senior author Dr. Roger Lo, an assistant professor of and molecular and and a Jonsson Cancer Center scientist.

"This study is a good example of why scientists should not always rely on what we expect to find," Lo said. "We expected that this second mutation was involved in and it wasn't. We also expected that only one mutation would exist in this signaling pathway, and that also was wrong."

The study appears April 1, 2012 in the early online edition of Cancer Discovery, a peer-reviewed journal of the American Association of .

About 50 percent of patients with metastatic , or 4,000 people a year, have the BRAF mutation and can be treated with the inhibitor Zelboraf, two pills taken twice daily. Zelboraf was approved by the U.S. for use in in August 2011. Many other common human cancers, including colon, and lung, also harbor BRAF-mutated subsets, Lo said.

Use of BRAF inhibitors led to a response in about 60 percent of those with the mutation, Lo said. After responding initially, most of those patients become resistant to the drug. Lo and his team of Jonsson Cancer Center scientists have been studying the mechanisms of resistance to see if they can either prevent it or find a way to re-sensitize the tumor to treatment. It was part of this work that led Lo to examine what role the MEK1 mutation might or might not be playing in that resistance.

"MEK1 is rarely mutated in cancers, but we found in this study that it was frequently associated with BRAF mutations," Lo said. "The presence of both mutated MEK1 and BRAF might have been considered a biomarker for patients who would not respond to BRAF inhibitors. We were quite surprised when we found that patients with both mutations respond to BRAF inhibitors as well as those with only the BRAF mutation."

To explore the association between the two mutations, Lo and his team analyzed tumor samples from 31 melanoma patients treated with a BRAF inhibitor. Among those patients, 16 percent of samples carried the double mutations in tumors before the cancer was treated, Lo said. The findings were confirmed use melanoma cells lines grown in Lo's laboratory.

Going forward, Lo and his team will look at approaches using inhibitors of MEK1 with BRAF inhibitors to determine if patients with the double mutations respond better and for longer periods. They will also try to understand why MEK1 mutations occur quite frequently among melanomas. About 15 percent of the patients with also have a mutated MEK1, Lo said. "As BRAF inhibitors gain widespread use for advance melanoma treatment, biomarkers for drug sensitivity or resistance are urgently needed," the study states. "We identify here concurrent activating mutations in BRAF and MEK1 in melanomas and show that the presence of a downstream mutation in MEK1 does not necessarily make BRAF mutant melanomas resistant to BRAF inhibitors." About 70,000 new cases of melanoma are diagnosed each year in the United States. Of those, 8,000 people will die of the disease.

Explore further: Scientists uncover mechanism for melanoma drug resistance

Related Stories

Scientists uncover mechanism for melanoma drug resistance

March 6, 2012
Cancer is tough to kill and has many ways of evading the drugs used by oncologists to try and eliminate it.

New drug, Vemurafenib, doubles survival of metastatic melanoma patients

March 1, 2012
A report published this week in the New England Journal of Medicine shows that the 50 percent of metastatic melanoma patients with a specific genetic mutation benefit from the drug Vemurafenib – increasing median survival ...

Combo therapies tested to overcome drug resistance in melanoma patients

August 2, 2011
About 50 to 60 percent of patients with melanoma have a mutation in the BRAF gene that drives the growth of their cancer. Most of these patients respond well to two novel agents being studied in clinical trials that inhibit ...

Study uncovers mechanism by which melanoma drug accelerates secondary skin cancers

January 18, 2012
Patients with metastatic melanoma taking the recently approved drug vemurafenib (Zelboraf) responded well to the twice daily pill, but some of them developed a different, secondary skin cancer. Now, researchers at UCLA's ...

Recommended for you

CAR-T immunotherapy may help blood cancer patients who don't respond to standard treatments

October 20, 2017
Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis is one of the first centers nationwide to offer a new immunotherapy that targets certain blood cancers. Newly approved ...

Researchers pinpoint causes for spike in breast cancer genetic testing

October 20, 2017
A sharp rise in the number of women seeking BRCA genetic testing to evaluate their risk of developing breast cancer was driven by multiple factors, including celebrity endorsement, according to researchers at the University ...

Study shows how nerves drive prostate cancer

October 19, 2017
In a study in today's issue of Science, researchers at Albert Einstein College of Medicine, part of Montefiore Medicine, report that certain nerves sustain prostate cancer growth by triggering a switch that causes tumor vessels ...

Gene circuit switches on inside cancer cells, triggers immune attack

October 19, 2017
Researchers at MIT have developed a synthetic gene circuit that triggers the body's immune system to attack cancers when it detects signs of the disease.

One to 10 mutations are needed to drive cancer, scientists find

October 19, 2017
For the first time, scientists have provided unbiased estimates of the number of mutations needed for cancers to develop, in a study of more than 7,500 tumours across 29 cancer types. Researchers from the Wellcome Trust Sanger ...

Researchers target undruggable cancers

October 19, 2017
A new approach to targeting key cancer-linked proteins, thought to be 'undruggable," has been discovered through an alliance between industry and academia.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.